Loading…

Loading grant details…

Active HORIZON European Commission

SPACTORY, revolutionising pharmaceutical development and manufacturing through microgravity


Funder European Commission
Recipient Organization Spacepharma R&D Israel Ltd
Country Israel
Start Date Aug 01, 2024
End Date Jul 31, 2026
Duration 729 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 101189238
Grant Description

Over 2,000 R&D experiments have been done in Space until now.

Space near-zero gravity yields biochemical crystals orders of magnitude more defined, pure, uniform, and precise than in terrestial environments.

The low-gravity accelerates the development and preclinical testing of complex molecules e.g. proteins- and unleashes the potential of innovative high-value mAbs therapies, saving patients lives and improving their QoL.To make it real, after 11 space missions, SPACEPHARMA is committed to bringing the first mAbs factory to Space.

MOTI, the main SPACTORY building block, brings accessible, scalable, and affordable microgravity manufacturing controlled from Earth and able to fly in any satellite compatible with any launcher.

For our customers, the pharma industry, it means shorter time to Space, faster market access and affordable drug development. For SPACEPHARMA, it is a paradigm shift from drug R&D to manufacturing. For EU, it means leading the spatial race in drug development.

All Grantees

Spacepharma R&D Israel Ltd

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant